Comparative Pharmacology
Head-to-head clinical analysis: AGGRENOX versus PYRIDAMAL 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRENOX versus PYRIDAMAL 100.
AGGRENOX vs PYRIDAMAL 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aggrenox is a combination of dipyridamole and aspirin. Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, leading to increased extracellular adenosine which stimulates platelet adenylate cyclase, increasing cAMP levels and inhibiting platelet aggregation. Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1), inhibiting thromboxane A2 synthesis, thereby reducing platelet aggregation.
Dipyridamole inhibits platelet phosphodiesterase, reducing platelet aggregation; also inhibits adenosine deaminase and increases extracellular adenosine, leading to vasodilation.
One capsule (dipyridamole 200 mg plus aspirin 25 mg) orally twice daily.
100 mg orally three times daily.
None Documented
None Documented
Aspirin: 15-20 minutes for parent drug; salicylate terminal half-life 3-6 hours (dose-dependent). Dipyridamole: terminal half-life approximately 10-12 hours. Clinical context: Typical twice-daily dosing maintains therapeutic antiplatelet effect.
Terminal half-life 10-12 hours; clinical context: steady state achieved in 3-5 days; renal impairment prolongs half-life
Aspirin: renal elimination of salicylate and metabolites (primarily salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, and gentisic acid) accounts for >90% of a dose. Dipyridamole: primarily biliary excretion as glucuronide conjugates (enteric recycling); renal excretion accounts for <5% of unchanged drug.
Renal: 50-70% unchanged; biliary/fecal: 20-30% as metabolites; total renal elimination ~85%
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent